The DOI matches its Crossref record; 202 of the 206 references it cites were found in a registry or an index.
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Open accessAbstract
Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,242 new deaths in 2018 (GLOBOCAN 2018 estimates). Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate still stands at 9% only. To date, the causes of pancreatic carcinoma are still insufficiently known, although certain risk factors have been identified, such as tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, age, ethnicity, family history and genetic factors, Helicobacter pylori infection , non-O blood group and chronic pancreatitis. In general population, screening of large groups is not considered useful to detect the disease at its early stage, although newer techniques and the screening of tightly targeted groups (especially of those with family history), are being evaluated. Primary prevention is considered of utmost importance. Up-to-date statistics on pancreatic cancer occurrence and outcome along with a better understanding of the etiology and identifying the causative risk factors are essential for the primary prevention of this disease. World J Oncol. 2019;10(1):10-27 doi: https://doi.org/10.14740/wjon1166
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Map shows estimated age-standardized incidence rates (ASR) for pancreatic cancer worldwide in 2018, including both sexes and all ages (reproduced from http://globocan.iarc.fr/ [2]).](/paper-figures/011d0f92315d4c47a23b4ba7e1b2211c/epidemiology-of-pancreatic-cancer-global-trends-etiology-and-risk-factors-figure-1.jpg)
![Figure 2 (a) Bar chart shows country-specific incidence age-standardized rates by sex for pancreatic cancer in 2018. Source: GLOBOCAN 2018 [2]. (b) Bar chart shows country-specific mortality age-standardized rates by sex for pancreatic cancer in 2018. Source: GLOBOCAN 2018 [2].](/paper-figures/330c50eb2dae4b48af0b334a846cb4e5/epidemiology-of-pancreatic-cancer-global-trends-etiology-and-risk-factors-figure-2.jpg)
![Figure 3 Map shows estimated age-standardized mortality rates (ASR) for pancreatic cancer worldwide in 2018, including both sexes and all ages (reproduced from http://globocan.iarc.fr/ [2]).](/paper-figures/d7b25817da12464bb57687ab8f252484/epidemiology-of-pancreatic-cancer-global-trends-etiology-and-risk-factors-figure-3.jpg)
![Figure 4 Bar chart shows estimated age-standardized incidence and mortality rates (ASR) for pancreatic cancer in world areas in 2018, including both sexes and all ages (reproduced from http://globocan.iarc.fr/ [2]).](/paper-figures/9011e3a91fed4edeb99e7c1c8c31ef19/epidemiology-of-pancreatic-cancer-global-trends-etiology-and-risk-factors-figure-4.jpg)
![Figure 5 Trends in pancreatic cancer incidence and mortality predicted for the years 2018 to 2040 (reproduced from http://globocan.iarc.fr/ [28]). (a) Estimated incidence from 2018 to 2040, in both sexes and all ages (0 - 70+ years). Asia: 214,499 in 2018 and +190,532 in 2040, (+88.8% of increase); Europe: 132,559 in 2018 and +38,855 in 2040 (+29.3%); North America: 56,002 in 2018 and +28,325 in 2040 (+50.6%); Africa: 16,059 in 2018 and +18,327 in 2040 (+114.1%); Latin America and the Caribbean: 35,270 in 2018 and +35,007 in 2040 (+99.3%); Oceania: 4,529 in 2018 and +3,268 in 2040 (+72.2%). (b) Estimated mortality from 2018 to 2040, in both sexes and all ages (0 to 70+ years). Asia: 200,681 in 2018 and +182,127 in 2040 (+90.8%); Europe: 128,045 in 2018 and +40,444 in 2040 (+31.6%); North America: 50,745 in 2018 and +29,011 in 2040 (57.2%); Africa: 15,458 in 2018 and +17,744 in 2040 (+114.8%); Latin America and the Caribbean: 33,311 in 2018 and +33,637 in 2040 (+101.0%); Oceania: 4,002 in 2018 and +2,985 in 2040 (74.6%)](/paper-figures/916959fdc9124fd9b6d053c3f7256a4f/epidemiology-of-pancreatic-cancer-global-trends-etiology-and-risk-factors-figure-5.jpg)
![Figure 6 Pancreatic cancer, age-standardized 1-year and 5-year net survival, adults (age: 15 - 99 years), England and Wales 1971 - 2011 (reproduced from reference [34]).](/paper-figures/3681d530d4d047ddb5a95b1764c8cab7/epidemiology-of-pancreatic-cancer-global-trends-etiology-and-risk-factors-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two major PC subtypes are pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumours (PNETs), with PDAC being the more aggressive subtype and accounting for 90% of all PC cases [2, 3].”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models (2024) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,632
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
Ferlay, J., Steliarova‐Foucher, E., Lortet‐Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., Forman, D., & Bray, F. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.027 · Cited by 5,243
Parkin, D. M., Pisani, P., & Ferlay, J. (1999) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.49.1.33 · Cited by 3,398
Vincent, A., Herman, J. M., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,678
Cancer is a preventable disease that requires major lifestyle changes
Anand, P., Kunnumakara, A. B., Sundaram, C., Harikumar, K. B., Tharakan, S. T., Lai, O. S., Sung, B., & Aggarwal, B. B. (2008) · Pharmaceutical Research · doi:10.1007/s11095-008-9661-9 · Cited by 2,632
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
Cited by
Sorted by citations
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Park, W., Chawla, A., & O'Reilly, E. M. (2021) · JAMA · doi:10.1001/jama.2021.13027 · Cited by 2,040
Photodynamic and Photothermal Therapies: Synergy Opportunities for Nanomedicine
Overchuk, M., Weersink, R., Wilson, B. C., & Zheng, G. (2023) · ACS Nano · doi:10.1021/acsnano.3c00891 · Cited by 1,375
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Rose, M., Burgess, J. T., O'Byrne, K. J., Richard, D. J., & Bolderson, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.564601 · Cited by 775
Chemoresistance in Pancreatic Cancer
Zeng, S., Pöttler, M., Lan, B., Grützmann, R., Pilarsky, C. P., & Yang, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184504 · Cited by 613
Pancreatic cancer: A review of epidemiology, trend, and risk factors
Hu, J.-X., Zhao, C., Chen, W.-B., Liu, Q., Li, Q.-W., Lin, Y., & Gao, F. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i27.4298 · Cited by 643
Tsilimigras, D. I., Brodt, P., Clavien, P., Muschel, R. J., D'Angelica, M. I., Endo, I., Parks, R. W., Doyle, M. B., de Santibáñes, E., & Pawlik, T. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00261-6 · Cited by 584
Wainberg, Z. A., Melisi, D., Macarulla, T. M., Pazo-Cid, R., Chandana, S. R., de la Fouchardière, C., Dean, A. P., Kišš, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 548
Role of microbiota-derived short-chain fatty acids in cancer development and prevention
Mirzaei, R., Afaghi, A., Babakhani, S., Sohrabi, M., Hosseini‐Fard, S. R., Babolhavaeji, K., Akbari, S. K. A., Yousefimashouf, R., & Karampoor, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111619 · Cited by 416
Salvi, M., Acharya, U. R., Molinari, F., & Meiburger, K. M. (2020) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2020.104129 · Cited by 420
Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369
Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment
Zhao, Z., & Liu, W. C. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820962117 · Cited by 377
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
Tang, B., Yang, Y., Kang, M., Wang, Y., Wang, Y., Bi, Y., He, S., & Shimamoto, F. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1128-6 · Cited by 326
RetractedThe β1-adrenergic receptor links sympathetic nerves to T cell exhaustion
Globig, A.-M., Zhao, S., Roginsky, J., Maltez, V. I., Güiza, J., Avina-Ochoa, N., Heeg, M., Hoffmann, F. A., Chaudhary, O., Wang, J., et al. (2023) · Nature · doi:10.1038/s41586-023-06568-6 · Cited by 331
Rauniyar, A., Hagos, D. H., Jha, D., Håkegård, J. E., Bagci, U., Rawat, D. B., & Vlassov, V. (2024) · IEEE Internet of Things Journal · doi:10.1109/jiot.2023.3329061 · Cited by 315
Burden of Pancreatic Cancer: From Epidemiology to Practice
Khalaf, N., El-Serag, H. B., Abrams, H. R., & Thrift, A. P. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.054 · Cited by 308
Microbiota in pancreatic health and disease: the next frontier in microbiome research
Thomas, R. M., & Jobin, C. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0242-7 · Cited by 311
A faecal microbiota signature with high specificity for pancreatic cancer
Kartal, E., Schmidt, T. S. B., Molina-Montes, E., Rodríguez-Perales, S., Wirbel, J., Maistrenko, O. M., Akanni, W. A., Alashkar Alhamwe, B., Alves, R. J., Carrato, A., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324755 · Cited by 290
Zhou, D. C., Jayasinghe, R. G., Chen, S., Herndon, J. M., Iglesia, M. D., Navale, P., Wendl, M. C., Caravan, W., Sato, K., Storrs, E. P., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01157-1 · Cited by 290
RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Qu, J., Yan, H., Hou, Y., Cao, W., Liu, Y., Zhang, E., He, J., & Cai, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01224-4 · Cited by 270
Kurz, E., Hirsch, C. A., Dalton, T., Shadaloey, S. A., Khodadadi-Jamayran, A., Miller, G., Pareek, S., Rajaei, H., Mohindroo, C., Baydogan, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.006 · Cited by 258
Zhang, Z., Tang, H., Chen, P., Xie, H., & Tao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0074-5 · Cited by 263
Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01604 · Cited by 244
Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Zhang, T., Ren, Y., Yang, P., Wang, J., & Zhou, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05351-1 · Cited by 240
Melisi, D., Oh, D., Hollebecque, A., Calvo, E., Varghese, A. M., Borazanci, E. H., Macarulla, T. M., Merz, V., Zecchetto, C., Zhao, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002068 · Cited by 216
The pancreatic cancer genome revisited
Hayashi, A., Hong, J., & Iacobuzio-Donahue, C. A. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00463-z · Cited by 211
Nagata, N., Nishijima, S., Kojima, Y., Hisada, Y., Imbe, K., Miyoshi-Akiyama, T., Suda, W., Kimura, M., Aoki, R., Sekine, K., et al. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.054 · Cited by 209
Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection
Fahrmann, J. F., Schmidt, C. M., Mao, X., Irajizad, E., Loftus, M., Zhang, J., Patel, N., Vykoukal, J., Dennison, J. B., Long, J. P., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.11.052 · Cited by 208
Treatment landscape of metastatic pancreatic cancer
Dosso, S. D., Siebenhüner, A. R., Winder, T., Meisel, A., Fritsch, R., Astaras, C., Szturz, P., & Borner, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102180 · Cited by 212
Tan, Q., Ma, X., Yang, B., Liu, Y., Xie, Y., Wang, X., Yuan, W., & Ma, J. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2073785 · Cited by 193
Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma
Latenstein, A. E. J., van der Geest, L. G., Bonsing, B. A., Koerkamp, B. G., Mohammad, N. H., de Hingh, I. H. J. T., de Meijer, V. E., Molenaar, I. Q., van Santvoort, H. C., van Tienhoven, G., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.002 · Cited by 192
Early-Onset Cancer in the Gastrointestinal Tract Is on the Rise—Evidence and Implications
Ben‐Aharon, I., van Laarhoven, H. W. M., Fontana, E., Obermannova, R. L., Nilsson, M., & Lordick, F. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1038 · Cited by 171
Orhan, A., Vogelsang, R. P., Andersen, M. B., Madsen, M. T., Hölmich, E. R., Raskov, H., & Gögenür, I. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.013 · Cited by 170
The global burden of pancreatic cancer
Lippi, G., & Mattiuzzi, C. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.94845 · Cited by 162
Youness, R. A., Kamel, R., ElKasabgy, N. A., Shao, P., & Farag, M. A. (2021) · Molecules · doi:10.3390/molecules26051486 · Cited by 159
Mechanisms of T-Cell Exhaustion in Pancreatic Cancer
Saka, D., Gökalp, M., Piyade, B., Çevik, N. C., Sever, E. A., Unutmaz, D., Ceyhan, G. O., Demir, İ. E., & Asimgil, H. (2020) · Cancers · doi:10.3390/cancers12082274 · Cited by 160
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149
Pritchett, N. R., Spangler, E. C., Gray, G. M., Livinski, A. A., Sampson, J. N., Dawsey, S. M., & Jones, R. R. (2022) · Environmental Health Perspectives · doi:10.1289/ehp9620 · Cited by 145
Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?
O'Neill, R. S., & Stoita, A. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i26.4045 · Cited by 144
Nimmakayala, R. K., Leon, F., Rachagani, S., Rauth, S., Nallasamy, P., Marimuthu, S., Shailendra, G. K., Chhonker, Y. S., Chugh, S., Chirravuri, R., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01518-2 · Cited by 144
Cappellesso, F., Orban, M., Shirgaonkar, N., Berardi, E., Serneels, J., Neveu, M.-A. C., Molfetta, D. D., Piccapane, F., Caroppo, R., Debellis, L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00470-2 · Cited by 141
Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis
Kajioka, H., Kagawa, S., Ito, A., Yoshimoto, M., Sakamoto, S., Kikuchi, S., Kuroda, S., Yoshida, R., Umeda, Y., Noma, K., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.10.015 · Cited by 135
Kumar, S., Schoonderwoerd, M. J. A., Kroonen, J. S., de Graaf, I. J., Sluijter, M., Ruano, D., González‐Prieto, R., Vries, M. V., Rip, J., Arens, R., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324834 · Cited by 130
Pancreatic cancer in 2021: What you need to know to win
Tonini, V., & Zanni, M. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i35.5851 · Cited by 133
Panebianco, C., Villani, A., Pisati, F., Orsenigo, F., Ulaszewska, M., Latiano, T. P., Potenza, A., Andolfo, A., Terracciano, F., Tripodo, C., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113163 · Cited by 126
Coumarin–benzimidazole hybrids: A review of developments in medicinal chemistry
G, A. C., Gondru, R., Li, Y., & Banothu, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113921 · Cited by 124
Emerging roles for the IL-6 family of cytokines in pancreatic cancer
van Duijneveldt, G., Griffin, M. D. W., & Putoczki, T. L. (2020) · Clinical Science · doi:10.1042/cs20191211 · Cited by 126
LOX-1 and cancer: an indissoluble liaison
Murdocca, M., Masi, C. D., Pucci, S., Mango, R., Novelli, G., Natale, C. D., & Sangiuolo, F. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-00279-0 · Cited by 121
Therapeutic resistance of pancreatic cancer: Roadmap to its reversal
Yu, S., Zhang, C., & Xie, K. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188461 · Cited by 119
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer
Al-Shaheri, F. N., Alhamdani, M. S. S., Bauer, A. S., Giese, N. A., Büchler, M. W., Hackert, T., & Hoheisel, J. D. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102193 · Cited by 119
Ragupathi, A., Singh, M., Perez, A. M., & Zhang, D. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1133472 · Cited by 120
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Differential contribution of pancreatic fibroblast subsets to the pancreatic cancer stroma
Garcia, P. E., Adoumie, M., Kim, E. C., Zhang, Y., Scales, M. K., El-Tawil, Y. S., Shaikh, A. Z., Wen, H.-J., Bednar, F., Allen, B. L., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.05.004 · Cited by 110
“survival rate for PDAC is only 10%, which can be attributed to the aggressive and chemoresistant nature of the cancer, in addition to the frequently late diagnosis.(2) In PDAC, more”
BackgroundKoltai, T., Reshkin, S. J., Carvalho, T. M. A., Molfetta, D. D., Greco, M. R., Alfarouk, K. O., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14102486 · Cited by 119
Sohel, M., Sultana, H., Sultana, T., Amin, M. A., Aktar, S., Ali, M. C., Rahim, Z. B., Hossain, M. A., Mamun, A. A., Amin, M. N., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e08815 · Cited by 108
Alkaliptosis: a new weapon for cancer therapy
Liu, J., Kuang, F., Kang, R., & Tang, D. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0134-6 · Cited by 106
Poh, A. R., & Ernst, M. (2021) · Cancers · doi:10.3390/cancers13122860 · Cited by 106
Liu, J., Chen, C., Wei, T., Gayet, O., Loncle, C., Borge, L., Dusetti, N., Ma, X., Marson, D., Laurini, E., et al. (2021) · Exploration · doi:10.1002/exp.20210003 · Cited by 104
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
Samanta, K., Setua, S., Kumari, S., Jaggi, M., Yallapu, M. M., & Chauhan, S. C. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110574 · Cited by 105
Partyka, O., Pajewska, M., Kwaśniewska, D., Czerw, A. I., Deptała, A., Budzik, M. P., Cipora, E., Gąska, I., Gazdowicz, L., Mielnik, A., et al. (2023) · Cancers · doi:10.3390/cancers15143634 · Cited by 103
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Frampton, J. E. (2020) · Drugs · doi:10.1007/s40265-020-01336-6 · Cited by 102
de la Iglesia, D., Avci, B., Kiriukova, M. A., Panić, N., Bozhychko, M., Şandru, V., de‐Madaria, E., & Capurso, G. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620938987 · Cited by 100
Chen, S.-M., Chieng, W.-W., Huang, S., Hsu, L., & Jan, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-77322-5 · Cited by 99
Targeting KRAS in pancreatic cancer
Stickler, S., RATH, B., & Hamilton, G. (2024) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2024.045356 · Cited by 105
Leiphrakpam, P. D., Chowdhury, S., Zhang, M. H., Bajaj, V., Dhir, M., & Are, C. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01183-2 · Cited by 99
Wang, Z., Hausmann, S., Lyu, R., Li, T., Lofgren, S., Flores, N. M., Fuentes, M. E., Caporicci, M., Yang, Z., Meiners, M. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.014 · Cited by 98
Doocey, C. M., Finn, K., Murphy, C. P., & Guinane, C. M. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02465-6 · Cited by 98
Talukdar, P. D., & Chatterji, U. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01651-w · Cited by 103
Advances in Gold Nanoparticle-Based Combined Cancer Therapy
Bromma, K., & Chithrani, D. B. (2020) · Nanomaterials · doi:10.3390/nano10091671 · Cited by 96
Oral microbiome and pancreatic cancer
Wei, A.-L., Mao, L., Li, G., Wang, X., Hu, W.-M., Li, Z., Yuan, J., Liu, H.-Y., Zhou, L.-L., Li, K., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i48.7679 · Cited by 95
Proteomics, Personalized Medicine and Cancer
Su, M., Zhang, Z., Zhou, L., Han, C., Huang, C., & Nice, E. C. (2021) · Cancers · doi:10.3390/cancers13112512 · Cited by 93
The Role of Exosomes in Pancreatic Cancer
Lan, B., Zeng, S., Grützmann, R., & Pilarsky, C. P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184332 · Cited by 94
He, C., Huang, X., Zhang, Y. L., Lin, X., & Li, S. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.39 · Cited by 93
Bassi, C., Marchegiani, G., Giuliani, T., Gioia, A. D., Andrianello, S., Zingaretti, C. C., Brentegani, G., Pastena, M. D., Fontana, M., Pea, A., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000004753 · Cited by 91
Hirt, C., Booij, T. H., Grob, L., Simmler, P., Toussaint, N. C., Keller, D., Taube, D., Ludwig, V., Goryachkin, A., Pauli, C., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100095 · Cited by 92
Ramakrishnan, P., Loh, W. M., Gopinath, S. C. B., Bonam, S. R., Fareez, I. M., Guad, R. M., Sim, M. S., & Wu, Y. S. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.008 · Cited by 90
CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
Harvey, J. B., Phan, L. H., Villarreal, O. E., & Bowser, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00508 · Cited by 88
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
Nicolle, R., Gayet, O., Duconseil, P., Vanbrugghe, C., Roques, J., Bigonnet, M., Blum, Y., Elarouci, N., Armenoult, L., Ayadi, M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.601 · Cited by 97
Gender Differences in Obesity-Related Cancers
Argyrakopoulou, G., Dalamaga, Μ., Spyrou, N., & Kokkinos, A. D. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00426-0 · Cited by 88
Salivary MicroRNA for Diagnosis of Cancer and Systemic Diseases: A Systematic Review
Setti, G., Pezzi, M. E., Viani, M. V., Pertinhez, T. A., Cassi, D., Magnoni, C., Bellini, P., Musolino, A., Vescovi, P., & Meleti, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030907 · Cited by 84
Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?
Slapak, E. J., Duitman, J., Tekin, C., Bijlsma, M. F., & Spek, C. A. (2020) · Biology · doi:10.3390/biology9040080 · Cited by 84
BioMOF-Based Anti-Cancer Drug Delivery Systems
Elmehrath, S., Nguyen, H. L., Karam, S. M., Amin, A., & Greish, Y. E. (2023) · Nanomaterials · doi:10.3390/nano13050953 · Cited by 83
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
Reyes‐Castellanos, G., Masoud, R., & Carrier, A. (2020) · Biomedicines · doi:10.3390/biomedicines8080270 · Cited by 85
Cao, S., Saw, P. E., Shen, Q., Li, R., Liu, Y., & Xu, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121264 · Cited by 83
Sivaramakarthikeyan, R., Iniyaval, S., Saravanan, V., Lim, W., Mai, C., & Ramalingan, C. (2020) · ACS Omega · doi:10.1021/acsomega.0c00630 · Cited by 81
d-Pinitol: a cyclitol with versatile biological and pharmacological activities
Sánchéz‐Hidalgo, M., León‐González, A. J., Gálvez‐Peralta, M., González-Mauraza, N. H., & Martı́n-Cordero, C. (2020) · Phytochemistry Reviews · doi:10.1007/s11101-020-09677-6 · Cited by 80
Ashrafizadeh, M., Zhang, W., Zou, R., Sethi, G., Klionsky, D. J., & Zhang, X. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106822 · Cited by 79
Molecular mediators of peritoneal metastasis in pancreatic cancer
Avula, L. R., Hagerty, B. L., & Alewine, C. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09924-4 · Cited by 79
Khan, A. A., Liu, X., Yan, X., Tahir, M., Ali, S., & Huang, H. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09952-0 · Cited by 78
Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer
Bhat, A. A., Goyal, A., Thapa, R., Almalki, W. H., Kazmi, I. A., Alzarea, S. I., Singh, M., Rohilla, S., Saini, T. K., Kukreti, N., et al. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156376 · Cited by 78
Garcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77
Cho, J., Scragg, R. K. R., & Petrov, M. S. (2020) · Diabetes Care · doi:10.2337/dc20-0207 · Cited by 77
Chalabi‐Dchar, M., Fenouil, T., Machon, C., Vincent, A., Catez, F., Marcel, V., Mertani, H. C., Saurin, J., Bouvet, P., Guitton, J., et al. (2021) · NAR Cancer · doi:10.1093/narcan/zcab032 · Cited by 77
Dahlem, C., Barghash, A., Puchas, P., Haybaeck, J., & Kessler, S. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133204 · Cited by 76
Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer
Pezzilli, R., Caccialanza, R., Capurso, G., Brunetti, O., Milella, M., & Falconi, M. (2020) · Cancers · doi:10.3390/cancers12020275 · Cited by 76
Yang, J., Lin, P., Yang, M., Liu, W. C., Fu, X., Liu, D., Tao, L., Huo, Y., Zhang, J., Hua, R., et al. (2021) · Genome biology · doi:10.1186/s13059-020-02222-w · Cited by 76
Ye, J., Mills, B. N., Qin, S., Garrett-Larsen, J., Murphy, J. D., Uccello, T. P., Han, B. J., Vrooman, T. G., Johnston, C. J., Lord, E. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004784 · Cited by 76
Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
Pereira, M. A., & Chio, I. I. C. (2019) · Genes · doi:10.3390/genes11010006 · Cited by 75
Pancreatitis, Pancreatic Cancer, and Their Metabolic Sequelae: Projected Burden to 2050
Cho, J., & Petrov, M. S. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000251 · Cited by 75
Metadata
- Authors
- Rawla, P., Sunkara, T., & Gaduputi, V.
- Affiliations
- Sovah Health Martinsville (US)
- Mercy Medical Center (US)
- Corresponding author
- Rawla, Prashanth
- Venue
- World Journal of Oncology
- Publisher
- Elmer Press, Inc.
- Published
- 2019
- Volume
- 10
- Issue
- 1
- Pages
- 10-27
- ISSN
- 1920-4531 (ISSN-L)
- 1920-454X
- PMC
- PMC6396775
- OpenAlex
- W2917919815
- Cited by
- 2,269
- References
- 206
- Citations by year
- 2026: 147 · 2025: 246 · 2024: 320 · 2023: 372 · 2022: 435 · 2021: 415 · 2020: 271 · 2019: 63
- FWCI
- 28.47
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- World Journal of Oncology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- pancreatic cancer, epidemiology, cancer incidence, cancer mortality, risk factors, etiology, smoking, diabetes mellitus, obesity, alcohol abuse, chronic pancreatitis, Helicobacter pylori, family history (medicine), genetic susceptibility, cancer screening, primary prevention, five-year survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review